<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414685</url>
  </required_header>
  <id_info>
    <org_study_id>GCTSK003</org_study_id>
    <nct_id>NCT02414685</nct_id>
  </id_info>
  <brief_title>First Line TIP in Poor Prognosis TGCTs.</brief_title>
  <acronym>TIP</acronym>
  <official_title>A Treatment Strategy of the Use of 1st Line Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Based on Tumor Marker Decline: A Phase II Trial of Paclitaxel, Ifosfamid and Cisplatin Regimen.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Slovakia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Slovakia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TIP in the 1st line treatment of GCTs patients with unfavorable decline of serum tumor
      markers after 1 cycle of the BEP regimen.TIP will be administered to the patient until
      progression, unacceptable toxicity, complete response or inability of the subject to comply
      with study requirements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cycle 1: BEP regimen

      Serum tumor markers at day 18-21:

      â€¢Patients with an unfavorable pattern of tumor marker decrease after 1 cycle of BEP will
      receive 4 more cycles of TIP.

      TIP regimen:

        -  Taxol 250 mg/ m2 iv on day 1

        -  Ifosfamid 1,2 g/ m2/ day iv x 5 days

        -  Cisplatin 20 mg/ m2/ day iv x 5 days One cycle of therapy consists of 22 days. Estimated
           duration of treatment: Until progression, unacceptable toxicity, complete response or
           inability of the subject to comply with study requirements.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>36 month</time_frame>
    <description>according RECIST criteria version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>36 month</time_frame>
    <description>response rate after chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>36 month</time_frame>
    <description>expressed as median and as 12-weeks post-treatment initiation continuous progression-free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events grade III and IV</measure>
    <time_frame>36 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>Survival will be estimated from the registration date to the date of last follow-up or death. Patients will be followed at least 3 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Germ Cell Tumor</condition>
  <arm_group>
    <arm_group_label>intravenous chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TIP regimen:
Paclitaxel 250 mg/ m2 iv on day 1
Ifosfamide 1,2 g/ m2/ day iv x 5 days
Cisplatin 20 mg/ m2/ day iv x 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements</description>
    <arm_group_label>intravenous chemotherapy</arm_group_label>
    <other_name>paclitaxel ebewe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements</description>
    <arm_group_label>intravenous chemotherapy</arm_group_label>
    <other_name>ifosfamide-holoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements</description>
    <arm_group_label>intravenous chemotherapy</arm_group_label>
    <other_name>cisplatin-hospira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 16 years.

          -  Evidence of NSGCT based on histologic examination or based on clinical evidence and
             high serum HCG or AFP levels (in case of clinical emergency, therapy can be started
             before pathologic sample is obtained if tumor markers are very elevated)

          -  Testicular, retroperitoneal, or mediastinal primary site.

          -  Evidence of disseminated disease (clinical stages II or III).

          -  Disease classified as poor prognosis according to IGCCCG criteria:

          -  Primary mediastinal NSGCT or

          -  Non-pulmonary visceral metastases or

          -  HCG &gt; 50,000 UI/l, or AFP &gt; 10,000 ng/ml, or LDH &gt; 10 times the upper normal value.

          -  No prior chemotherapy.

          -  No previous carcinoma, except basal-cell carcinoma of the skin.

          -  Adequate renal function: measured or calculated creatinine clearance&gt; 60 ml/min.

          -  Absolute granulocyte count &gt;= 1,500/mm3, platelets &gt;= 100,000 mm3, bilirubine &lt;= 1.5
             fold the upper normal value.

          -  Unfavorable tumor marker decline after 1.cycle of BEP

          -  Signed informed consent.

        Exclusion Criteria:

          -  Patients infected by the Human Immunodeficiency Virus (HIV).

          -  Patients who do not fit inclusion criteria.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michal Mego, Ass.prof</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute, Slovakia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jozef Mardiak, Prof</last_name>
    <phone>+421259378</phone>
    <phone_ext>366</phone_ext>
    <email>jozef.mardiak@nou.sk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michal Mego, Ass.prof.</last_name>
    <phone>+421259378</phone>
    <phone_ext>366</phone_ext>
    <email>misomego@nou.sk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bratislava</city>
        <zip>83310</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Mego, Assoc. Prof</last_name>
      <phone>+421259378</phone>
      <phone_ext>366</phone_ext>
      <email>michal.mego@nou.sk</email>
    </contact>
    <contact_backup>
      <last_name>Jozef Mardiak, Prof</last_name>
      <phone>+421259378</phone>
      <phone_ext>108</phone_ext>
      <email>jozef.mardiak@nou.sk</email>
    </contact_backup>
    <investigator>
      <last_name>Jozef Mardiak, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michal Mego, Assoc. Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2015</study_first_submitted>
  <study_first_submitted_qc>April 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2015</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>poor-prognosis germ cell cancer, paclitaxel, ifosfamid and cisplatin regimen, tumor marker decline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

